NCT05951946Not yet recruiting
A Study to Evaluate Drug-drug Interactions and Safety Between BR3006-1, BR3006-2, and BR3006-3 in Healthy Volunteers
An Open Label, 6-sequence, 3-period Study to Evaluate Drug-drug Interactions and Safety Between BR3006-1, BR3006-2, and BR3006-3 in Healthy Volunteers
Boryung Pharmaceutical Co., LtdPhase 1ClinicalTrials.govdrug
Study focus
- Disease/Condition
- Diabetes Mellitus
- Drug/Device/Intervention
- BR3006-1
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Boryung Pharmaceutical Co., Ltd
- Location
- Seongnam-si, South Korea
Timeline & enrollment
- Phase
- Phase 1
- Start date
- Jul 01, 2023
- End date
- Sep 01, 2023
- Enrollment
- 36 participants
Primary outcome
AUCτ,ss,Cmax,ss
Summary
The purpose of this clinical trial is to evaluate drug-drug interactions and safety between
 BR3006-1, BR3006-2, and BR3006-3 in healthy volunteers
ICD-10 classifications
Diabetes mellitusUnspecified diabetes mellitusOther specified diabetes mellitusUnspecified diabetes mellitus without complicationsUnspecified diabetes mellitus with unspecified complications
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT05951946
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT05951946 through Pure Global AI's free database. This Phase 1 trial is sponsored by Boryung Pharmaceutical Co., Ltd and is currently Not yet recruiting. The study focuses on Diabetes Mellitus. Target enrollment is 36 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.